All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the EHA2021 Virtual Congress, the Lymphoma Hub spoke with Nilanjan Ghosh, Levine Cancer Institute, Charlotte, US. We asked, Do early clinical data show synergy between mosunetuzumab and polatuzumab vedotin in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL)?
Do early clinical data show synergy between mosunetuzumab and polatuzumab vedotin in R/R B-cell NHL?
In this video, Ghosh discusses the combination of mosunetuzumab and polatuzumab vedotin (conjugate antibody) based on results from a phase I study. He believes there is synergy between the two active agents and that they have the potential to induce durable complete remissions.
Antibody-based therapies add weight to immunotherapy concepts for R/R DLBCL
As part of the leadup to the Lymphoma Hub ESH Satellite Symposium, the Lymphoma Hub is happy to provide an overview of the existing and emerging treatment approaches for...
Challenges in the management and treatment of patients with relapsed/refractory DLBCL
The virtual Lymphoma Hub Satellite Symposium at the European School of Haematology (ESH)’s 2nd How to Diagnose and Treat: Lymphoma conference saw a panel of...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox